Health In Tech Reports Second Quarter 2026 Financial Results

Rhea-AI Summary

Health In Tech (Nasdaq: HIT) reported Q2 2026 revenue of $8.1 million, down from $9.3 million in Q2 2025, and a net loss of $2.5 million, or $(0.04) per diluted share, versus net income of $0.6 million a year earlier. First-half 2026 revenue was $16.8 million compared with $17.3 million, with a net loss of $4.1 million, or $(0.07) per diluted share.

Contracted Revenue totaled $32.3 million for first-half 2026, including $17.3 million recognized as GAAP revenue, with $14.0 million expected in second-half 2026 and $1.0 million in 2027. Pipeline Revenue was $66.3 million as of July 31, 2026. Distribution partners reached 933, up 19.9% year over year, and Platform Placed Plan Value was $84.0 million. Adjusted EBITDA was $(1.3) million in Q2 2026. The company reaffirmed its full-year 2026 revenue guidance of $45–$50 million and highlighted progress on its Three-Year Rate Stabilization Program and the planned second-half 2026 launch of its HitRix marketplace platform.

Positive

• Contracted Revenue $32.3M for first-half 2026, with $15.0M remaining to be recognized as GAAP revenue in second-half 2026 and 2027.
• Pipeline Revenue $66.3M as of July 31, 2026, including $1.9M contracted after quarter-end.
• Distribution partners 933, a 19.9% year-over-year increase as of June 30, 2026.
• 2026 revenue guidance reaffirmed at $45M to $50M despite current-period losses.
• Platform Placed Plan Value $84.0M as of June 30, 2026, indicating higher transaction volume on the platform.

Negative

• Q2 2026 revenue down to $8.1M from $9.3M in Q2 2025.
• Net loss $2.5M in Q2 2026 versus $0.6M net income in Q2 2025.
• First-half 2026 net loss $4.1M compared with $1.1M net income in first-half 2025.
• Adjusted EBITDA turned negative to $(1.3)M in Q2 2026 from $1.6M in Q2 2025.
• Cost of revenues $8.4M for first-half 2026 versus $5.7M in 2025, reducing gross profit.
• Cash and cash equivalents $6.5M at June 30, 2026, down from $7.7M at December 31, 2025, while current liabilities rose to $10.0M from $5.2M.

News Explained

At June 30, Health In Tech had $6.5 million cash, $6.2 million first-half operating cash use, and 53.9 million Class A shares outstanding.

Health In Tech reported unaudited second-quarter and first-half results for the periods ended June 30, 2026; the balance sheet shows $6.5 million of cash and 53.9 million Class A shares outstanding, so the disclosure adds a current liquidity snapshot and a higher share count for existing holders to assess.

Cash and cash equivalents were $6.5 million at June 30, 2026, while operating activities used $6.2 million during the first half of 2026.

Class A shares issued and outstanding were 53,858,083 at June 30, 2026, versus 46,006,000 at December 31, 2025.

Issuing additional shares increases the total share count and reduces an existing holder's percentage ownership absent offsetting changes.

These figures show cash remaining alongside substantial first-half operating cash use, while the larger disclosed Class A share count is an unfavorable ownership change for existing holders if the additional shares were newly issued.

Market Context

The effective S-3/A shelf, dated June 26, 2026, adds financing context to HIT's reaffirmed guidance ...

Analysis

The effective S-3/A shelf, dated June 26, 2026, adds financing context to HIT's reaffirmed guidance and reported losses. Low short positioning limits that specific risk signal, while conversion of pipeline revenue remains important to monitor.

Key Figures

Q2 Revenue: $8.1 million First-Half Revenue: $16.8 million Contracted Revenue: $32.3 million +5 more

8 metrics

Q2 Revenue $8.1 million Q2 2026, compared with $9.3 million in Q2 2025

First-Half Revenue $16.8 million First-half 2026, compared with $17.3 million in the prior-year period

Contracted Revenue $32.3 million First-half 2026

Pipeline Revenue $66.3 million As of July 31, 2026

Net Loss $2.5 million Q2 2026

Diluted EPS $(0.04) Q2 2026

Adjusted EBITDA $(1.3) million Q2 2026

Revenue Guidance $45 million to $50 million Reaffirmed full-year 2026 guidance

Previous Earnings Reports

5 past events · Latest: May 13 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Q1 earnings report	Positive	-20.1%	Revenue increased year over year while guidance was reiterated and losses continued.
Mar 25	FY earnings report	Positive	-11.1%	Full-year revenue, adjusted EBITDA, and net income increased year over year.
Nov 10	Q3 earnings report	Positive	-26.4%	Revenue and adjusted EBITDA grew while distribution partners expanded year over year.
Jul 21	Q2 earnings report	Positive	+25.2%	Revenue, adjusted EBITDA, cash, and distribution partners all increased year over year.
Apr 14	Q1 earnings report	Positive	+1.9%	Revenue and adjusted EBITDA increased alongside expanded enrolled employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

HIT's earnings announcements produced mixed outcomes, with three positive earnings events followed by negative price reactions.

Key Terms

contracted revenue, pipeline revenue, adjusted ebitda, pipe financing, +1 more

5 terms

contracted revenue financial

"Contracted Revenue totaled $32.3 million for first-half 2026"

Contracted revenue is the amount of money a business expects to receive because customers have signed binding agreements for goods or services over a set period. For investors it shows how much future cash is already promised, reducing uncertainty about sales — like having customers hand you a schedule of payments in advance — which helps assess growth potential, valuation and risk compared with one-off or uncertain sales.

pipeline revenue financial

"Pipeline Revenue was $66.3 million as of July 31, 2026"

Revenue expected from opportunities that are in a company’s sales or product development pipeline—deals, orders, or products not yet recognized as official sales but tracked at various stages toward completion. Investors watch pipeline revenue as a forward-looking signal of potential future sales, similar to tracking items moving through a retailer’s checkout line or leads progressing through a sales funnel, because it helps estimate how current activity may translate into reported revenue later.

adjusted ebitda financial

"Adjusted EBITDA was $(1.3) million for Q2 2026"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

pipe financing financial

"the capital raised through our recent PIPE financing"

Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.

u.s. gaap financial

"Under U.S. GAAP revenue recognition"

U.S. GAAP is a set of rules and standards that companies in the United States follow to prepare their financial reports. It helps ensure that financial information is consistent and clear, so investors and others can compare and understand a company's financial health easily.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Contracted Revenue of $32.3 Million as of June 30, 2026
Pipeline Revenue of $66.3 Million as of July 31, 2026
Distribution Partners Grew 19.9% Year Over Year

STUART, Fla., Aug. 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three and six months ended June 30, 2026.

Second Quarter and First-Half 2026 Highlights

• Distribution Partners, including brokers, third-party administrators ("TPAs") and agencies, reached 933 as of June 30, 2026, an increase of 19.9% year over year.
• Q2 2026 Revenue was $8.1 million, compared with $9.3 million in Q2 2025. First-half 2026 revenue was $16.8 million, compared with $17.3 million in the prior year period.
• Contracted Revenue¹ totaled $32.3 million for first-half 2026, of which $17.3 million was recognized as GAAP revenue in first-half 2026. The remaining $14.0 million and $1.0 million are expected to be recognized as GAAP revenue in second-half 2026 and in 2027, respectively.
• Pipeline Revenue² was $66.3 million as of July 31, 2026, of which $1.9 million was contracted subsequent to quarter end. The remaining $64.4 million represents policies in quoting or binding status, with an expected conversion rate of 15% to 40%.
• Net loss for Q2 2026 was $2.5 million, or $(0.04) per diluted share, compared to net income of $0.6 million, or $0.01 per diluted share, in Q2 2025, and $4.1 million for the first half of 2026, or $(0.07) per diluted share, compared to net income of $1.1 million, or $0.02 per diluted share, in first-half 2025.
• Adjusted EBITDA³ was $(1.3) million for Q2 2026 and $(2.6) million for first-half 2026, reflecting continued investment in distribution, technology, and product development.
• Platform Placed Plan Value ("PPPV")⁴ was $84.0 million as of June 30, 2026.

2026 Outlook and Beyond

As of July 31, 2026, the Company had approximately $66.3 million in Pipeline Revenue, of which $1.9 million was contracted, while the remaining $64.4 million is in the quoting or binding stage. Based on the Company's estimated conversion rate of 15% to 40%, the Pipeline Revenue in the quoting or binding stage is expected to generate approximately $9.7 million to $25.8 million of additional Contracted Revenue. Under U.S. GAAP revenue recognition, this is expected to result in approximately $3.1 million to $8.3 million of GAAP revenue recognized in 2026, with an additional $6.6 million to $17.5 million of GAAP revenue expected to be recognized in 2027.

With five more months remaining in 2026, the Company expects to continue expanding its Pipeline Revenue through new product launches and new system enhancement.   Supported by its growing base of Contracted Revenue, increasing forward revenue visibility, and continued pipeline development, the Company is reaffirming its full-year 2026 revenue guidance of $45 million to $50 million.

CEO Commentary

Tim Johnson, Chief Executive Officer of Health In Tech, commented, "We continued to execute against our long-term growth strategy during the quarter by investing in sales, marketing, and key talent, supported in part by the capital raised through our recent PIPE financing. These investments are designed to expand our distribution network, accelerate product innovation, and strengthen our execution capabilities. Our contracted book of business continued to grow, providing greater visibility into future revenue. We believe Contracted Revenue and Pipeline Revenue are meaningful operating metrics that complement our GAAP financial results by illustrating the strength of our sales pipeline, the pace of customer conversion, and our expected revenue trajectory."

Mr. Johnson continued, "We also made meaningful progress on several strategic initiatives that we believe position the Company for its next phase of growth. During the quarter, we contractually secured our first employer group for the Three-Year Rate Stabilization Program, a differentiated solution designed to provide employers with greater predictability in stop-loss pricing over a multi-year period. This represents an important milestone as we advance toward the program's anticipated launch in the capital markets. In parallel, we are engaged with several high-profile governmental organizations that are evaluating participation in the program, and we expect to provide additional updates in the coming months.

As we execute on our strategic roadmap, we remain on track to launch HitRix, our next-generation marketplace platform, in the second half of 2026. While our current eDIYBS platform has transformed AI-enabled underwriting through bindable stop-loss quoting and customized plan design, HitRix expands the application of AI across the entire self-funded stop-loss insurance ecosystem. The platform leverages advanced AI-powered document intelligence to automate data extraction across multiple document types, enable intelligent plan comparisons, and facilitate an integrated competitive bidding process within a unified digital marketplace. By connecting a broad network of brokers, carriers, TPAs, and employer groups, HitRix is designed to increase market transparency, expand access to competitive stop-loss solutions, streamline the placement process, and deliver better outcomes for all participants across the self-funded insurance value chain."

End Notes

1. Contracted Revenue represents the total revenue expected to be generated over the contractual term of self-funded health plan policies placed through the Company's platform. Standard self-funded plan policies generally have a contractual term of 12 months, while the Company's Three-Year Rate Stabilization Program is designed with a 36-month contractual term. Revenue is recognized under U.S. GAAP on a straight-line basis over the policy term, beginning on the policy's effective date. Accordingly, Contracted Revenue represents revenue that has been contractually secured but has not yet been fully recognized under U.S. GAAP, providing an indication of future revenue expected from existing contracts.
2. Pipeline Revenue represents revenue from self-funded plan policies that are being quoted, are in binding status, or have been contracted subsequent to the end of the reporting period. This metric reflects the entire contractual term of the underlying policies, some of which may not ultimately convert to revenue.
3. Adjusted EBITDA is a non-GAAP financial measure. Additional information and reconciliation of Adjusted EBITDA to its most comparable GAAP financial measure is provided in the "Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA" section of this release.
4. Platform Placed Plan Value ("PPPV") represents the aggregate contractual value of self-funded health plans with stop-loss insurance (self-funded stop-loss plans) placed through the Company's platform during the fiscal year through the applicable fiscal quarter end, measured over each plan's full contractual term of typically 12 or 36 months from the plan's effective date. PPPV reflects the total economic value flowing through the platform, including premium, claim funding, and administrative fees, and is a measure of platform transaction volume rather than an indication of the Company's own revenue or take rate.

Conference Call Details

Health In Tech will host a conference call to discuss its financial results for the second quarter of 2026 on August 13, 2026, at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

A live audio webcast will be available via the Investor Relations page of Health In Tech's website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Management uses Adjusted EBITDA to provide investors with additional insight into operational performance and to facilitate comparison with other companies in the industry. Adjusted EBITDA should not be considered an alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

Use of Forward‑Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech's operations, results of operations, growth strategy and liquidity.

About Health In Tech 

Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter ("MGUs") and third-party administrators ("TPAs"). Health In Tech's platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

 

Health In Tech, Inc.
Consolidated Statements of Operations
(Unaudited)
	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenues
Revenues from underwriting modeling (ICE)	$ 1,272,647	$ 2,090,576	$ 2,741,461	$ 4,442,560
Revenues from fees (SMR)	6,783,973	7,223,273	14,086,805	12,886,273
Total revenues	8,056,620	9,313,849	16,828,266	17,328,833
Cost of revenues	4,134,127	3,003,979	8,396,374	5,663,564
Gross profit	3,922,493	6,309,870	8,431,892	11,665,269
Operating expenses
Sales and marketing expenses	2,215,889	1,226,738	4,507,490	2,316,993
General and administrative expenses	4,269,094	3,775,453	7,724,652	7,022,218
Research and development expenses	875,811	582,609	1,796,206	1,120,330
Total operating expenses	7,360,794	5,584,800	14,028,348	10,459,541
Other income (expense):
Interest income	69,568	108,198	137,039	193,564
Other income	100,000	—	122,334	118,399
Other expense	(52,341)	—	(52,341)	—
Total other income, net	117,227	108,198	207,032	311,963
(Loss) income before income tax expense	(3,321,074)	833,268	(5,389,424)	1,517,691
Income tax benefit (expense)	809,888	(202,637)	1,289,957	(388,468)
Net (loss) income	(2,511,186)	630,631	(4,099,467)	1,129,223
Net loss attributable to noncontrolling interests	(162)	—	(162)	—
Net (loss) income attributable to common stockholders	$ (2,511,024)	$ 630,631	$ (4,099,305)	$ 1,129,223
Net (loss) income per share
Basic	$ (0.04)	$ 0.01	$ (0.07)	$ 0.02
Diluted	$ (0.04)	$ 0.01	$ (0.07)	$ 0.02
Weighted average common shares outstanding:
Basic	62,829,725	55,382,395	60,106,502	55,003,233
Diluted	62,829,725	55,632,357	60,106,502	57,004,070

 

Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA
(Unaudited)
	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Net (loss) income attributable to common stockholders	$ (2,511,024)	$ 630,631	$ (4,099,305)	$ 1,129,223
Interest income	(69,568)	(108,198)	(137,039)	(193,564)
Amortization expense	320,320	135,983	723,787	271,966
Income tax (benefit) expense	(809,888)	202,637	(1,289,957)	388,468
Stock-based compensation expense, including employer payroll taxes related to stock-based awards	959,969	707,963	1,403,808	1,201,134
Provision for credit losses on other receivables	739,773	—	739,773	—
Other non-recurring items	37,341	—	37,341	—
Total net adjustments	1,177,947	938,385	1,477,713	1,668,004
Adjusted EBITDA	$ (1,333,077)	$ 1,569,016	$ (2,621,592)	$ 2,797,227

 

Consolidated Balance Sheets
(Unaudited)
	June 30,	December 31,
	2026	2025
Assets
Current assets
Cash and cash equivalents	$ 6,514,813	$ 7,669,754
Accounts receivable, net	8,546,307	756,288
Loans receivable, net	847,993	815,995
Other receivables, net	3,392,082	3,467,814
Deferred offering costs	102,586	170,977
Prepaid expenses and other current assets	2,380,284	3,280,148
Total current assets	21,784,065	16,160,976
Non-current assets
Software	7,197,718	6,530,894
Operating lease - right-of-use assets	104,277	139,940
Long-term prepaid expenses	8,184	258,151
Deferred tax assets, net	540,436	—
Total non-current assets	7,850,615	6,928,985
Total assets	$ 29,634,680	$ 23,089,961
Liabilities and stockholders' equity
Current liabilities
Accounts payable and accrued expenses	$ 9,907,370	$ 4,188,811
Operating lease liabilities - current	81,225	76,195
Other current liabilities	—	891,598
Total current liabilities	9,988,595	5,156,604
Non-current liabilities
Deferred tax liabilities	—	757,675
Operating lease liabilities - non-current	21,713	63,617
Total non-current liabilities	21,713	821,292
Total liabilities	10,010,308	5,977,896
Stockholders' equity
Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 53,858,083 and 46,006,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	$ 53,858	$ 46,006
Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	11,700	11,700
Additional paid-in capital	18,365,473	11,834,121
Retained earnings	1,120,933	5,220,238
Noncontrolling interests	72,408	—
Total stockholders' equity	19,624,372	17,112,065
Total liabilities and stockholders' equity	$ 29,634,680	$ 23,089,961

 

Consolidated Statements of Cash Flows
(Unaudited)
	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Cash flows (used in) provided by operating activities:
Net (loss) income	$ (2,511,186)	$ 630,631	$ (4,099,467)	$ 1,129,223
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Bad debt (recovery) expense	(2,954)	5,990	(2,954)	5,990
Amortization expense	320,320	135,983	723,787	271,966
Provision for refund liability	—	175,698	108,402	955,743
Provision for credit losses on other receivables	739,773	—	739,773	—
Deferred tax benefit	(813,639)	(32,074)	(1,298,111)	(66,547)
Interest income	(15,999)	(15,999)	(31,998)	(31,998)
Stock-based compensation expense	959,320	707,963	1,325,882	1,201,134
Changes in operating assets and liabilities:
Accounts receivable	(4,805,705)	823,480	(7,787,065)	359,982
Other receivables	(59,704)	134,954	(71,444)	(3,354,582)
Prepaid expenses and other assets	350,442	455,844	798,039	(561,907)
Operating lease right-of-use assets and liabilities, net	(606)	18	(1,211)	37
Accounts payable and accrued expenses	2,927,618	(1,150,600)	4,364,800	2,269,897
Income taxes payable	—	(390,612)	—	(170,309)
Other current liabilities	—	—	(1,000,000)	—
Net cash (used in) provided by operating activities	(2,912,320)	1,481,276	(6,231,567)	2,008,629
Cash flows used in investing activities:
Development of software	(596,992)	(909,897)	(959,123)	(1,613,372)
Net cash used in investing activities	(596,992)	(909,897)	(959,123)	(1,613,372)
Cash flows (used in) provided by financing activities:
Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees	—		6,381,000	—
Payments of deferred offering costs	(199,440)	(8,250)	(243,608)	(106,339)
Contributions from noncontrolling interests	71,428	—	71,428	—
Taxes paid related to net share settlement of equity awards	(173,071)	—	(173,071)	—
Net cash (used in) provided by financing activities	(301,083)	(8,250)	6,035,749	(106,339)
(Decrease) increase in cash and cash equivalents	(3,810,395)	563,129	(1,154,941)	288,918
Cash and cash equivalents, beginning of the period	10,325,208	7,575,037	7,669,754	7,849,248
Cash and cash equivalents, end of the period	$ 6,514,813	$ 8,138,166	$ 6,514,813	$ 8,138,166
Supplemental disclosures of cash flow information:
Cash paid for interest	$  —	$  —	$  —	$  —
Cash paid for income taxes	$ 15,000	$ 625,323	$ 10,035	$ 625,323
Summary of noncash investing and financing activities:
Accrued deferred offering costs included in accounts payable and accrued expenses	$ 115,911	$  —	$ 215,911	$  —
Accrued development of software included in accounts payable and accrued expenses	430,386	265,243	430,386	265,243
Reclassification of deferred offering costs to additional paid-in capital upon private investment in public equity financing	75,030	—	527,910	—
Stock-based compensation capitalized for software development	10,617	—	19,454	—

 

Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/health-in-tech-reports-second-quarter-2026-financial-results-302851136.html

SOURCE Health In Tech, Inc.

FAQ

How did Health In Tech (HIT) perform financially in Q2 2026?

Health In Tech reported Q2 2026 revenue of $8.1 million and a net loss of $2.5 million, or $(0.04) per diluted share. According to the company, this compares with $9.3 million revenue and $0.6 million net income, or $0.01 per diluted share, in Q2 2025.

What are Health In Tech's contracted and pipeline revenues as of mid-2026?

Health In Tech reported $32.3 million in Contracted Revenue for first-half 2026 and $66.3 million in Pipeline Revenue as of July 31, 2026. According to the company, $17.3 million of Contracted Revenue was already recognized as GAAP revenue during first-half 2026.

What revenue guidance did Health In Tech (HIT) give for full-year 2026?

Health In Tech reaffirmed its full-year 2026 revenue guidance of $45 million to $50 million. According to the company, this outlook is supported by growing Contracted Revenue, increasing forward revenue visibility, and continued development of its $66.3 million Pipeline Revenue as of July 31, 2026.

How did Health In Tech's profitability and Adjusted EBITDA change in 2026?

Health In Tech moved from net income to net loss, reporting a first-half 2026 net loss of $4.1 million versus $1.1 million net income in 2025. According to the company, Adjusted EBITDA declined to $(1.3) million in Q2 2026 and $(2.6) million for first-half 2026.

How is Health In Tech's distribution network and Platform Placed Plan Value evolving?

Health In Tech's distribution partners reached 933 as of June 30, 2026, a 19.9% year-over-year increase. According to the company, Platform Placed Plan Value was $84.0 million, reflecting the aggregate contractual value of self-funded stop-loss plans placed through its platform year-to-date.

What strategic initiatives is Health In Tech (HIT) pursuing for future growth?

Health In Tech secured its first employer group for its Three-Year Rate Stabilization Program and plans to launch its HitRix marketplace platform in second-half 2026. According to the company, HitRix aims to extend AI across the self-funded stop-loss insurance ecosystem.

What does Health In Tech's Pipeline Revenue imply for future GAAP revenue?

Based on a 15%–40% estimated conversion rate, Health In Tech expects Pipeline Revenue in quoting or binding status to generate $3.1–$8.3 million of GAAP revenue in 2026. According to the company, an additional $6.6–$17.5 million is expected to be recognized in 2027.